Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 332-337

  Marshall, John L ^a   Hawkins, Michael J ^a   Tsang, Kwong Y ^a   Richmond, Ellen ^a   Pedicano, James E ^a   Zhu, MingZhu ^a   Schlom, Jeffrey ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADULT; AGED; ALLELE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOWLPOX VIRUS; HUMAN; MALE; MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 0032944458     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.332     Document Type: Article

References (27)

1. Rogers GT: Carcinoembryonic antigens and related glycoproteins: Molecular aspects and specificity. Biochim Biophys Acta 695:227-249, 1983
2. Muraro R, Wunderlich D, Thor A, et al: Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal human adult tissues. Cancer Res 45:5769-5780, 1985
3. Steward AM, Nixon D, Zamcheck N, et al: Carcinoembryonic antigen in breast cancer patients: Serum levels and disease progress. Cancer 33:1246-1252, 1974
4. Vincent RG, Chu TM: Carcinoembryonic antigen in patients with carcinoma of the lung. J Thorac Cardiovasc Surg 66:320-328, 1978
5. Ladenson JH, McDonald JM, Landt M, et al: Colorectal carcinoma and carcinoembryonic antigen (CEA). Clin Chem 26:1213-1220, 1980
6. Benchimol S, Fuks A, Jothy S, et al: Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57:327-334, 1989
7. Midiri G, Amanti C, Benedetti M, et al: CEA tissue staining in colorectal cancer patients. Cancer 55:2624-2629, 1985
8. Kodera Y, Isobe K, Yamauchi M, et al: Expression of carcinoembryonic antigen (CEA) and nonspecific crossreacting antigen (NCA) in gastrointestinal cancer: The correlation with degree of differentiation. Br J Cancer 68:130-136, 1993
9. Zimmerman W, Weber B, Ortlieb B, et al: Chromosomal localization of the carcinoembryonic antigen gene family and differential expression in various tumors. Cancer Res 48:2550-2554, 1988
10. Fuchs C, Krapf F, Kern P, et al: CEA-containing immune complexes in sera of patients with colorectal cancer and breast cancer: Analysis of complexed immunoglobulin classes. Cancer Immunol Immunother 26:180-184, 1988
11. Tsang KY, Zaremba S, Nieroda CA, et al: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87:982-990, 1995
12. Foon KA, Chakraborty M, John WJ, et al: Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 96:334-342, 1995
13. Fagerberg J, Samanci A, Yi Q, et al: Recombinant carcinoembryonic antigen and granulocyte-macrophage-colony stimulating factor for active immunization of colorectal carcinoma patients. J Immunother 19:461, 1996 (abstr)
14. Conry RM, Saleh MN, Schlom J, et al: Human immune response to carcinoembryonic antigen tumor vaccines. J Immunother 18:137, 1995 (abstr)
15. Philip R, Brunette E, Alters S, et al: Gene modified and peptide pulsed dendritic cells for the generation of active immunotherapy strategies. J Immunother 19:467, 1996 (abstr)
16. Alters SE, Gadea JR, Sorich M, et al: Dendritic cells pulsed with CEA peptide induce CEA specific CTL with restricted TCR repertoire. J Immunother 21:17-26, 1998
17. Kantor J, Irvine K, Abrams S, et al: Anti-tumor activity and immune responses induced by a recombinant vaccinia-carcinoembryonic antigen (CEA) vaccine. J Natl Cancer Inst 84:1084-1091, 1992
18. Kantor J, Irvine K, Abrams S, et al: Immunogenicity and safety of a recombinant vaccinia virus expressing the carcinoembryonic antigen (CEA)-vaccine in a non-human primate. Cancer Res 52:6917-6925, 1992
19. Tsang KY, Zhu MZ, Nieroda CA, et al: Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin Cancer Res 3:2439-2449, 1997
20. Zaremba S, Barzaga E, Zhu MZ, et al: Identification of an enhancer agonist CTL peptide from human carcinoembryonic antigen. Cancer Res 57:4570-4577, 1997
21. Hodge JW, McLaughlin JP, Kantor JA, et al: Diversified prime and boost protocols using recombinant vaccinia virus and recombinant nonreplicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 16:759-768, 1997
22. Taylor J, Paoletti E: Fowlpox virus as a vector in non-avian species. Vaccine 6:466-468, 1988
23. Fries LF, Tartaglia J, Taylor J, et al: Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative poxvirus vector system. Vaccine 14:428-434, 1996
24. Tartaglia J, Weinberg R, Languet B, et al: A highly attenuated strain of vaccinia virus. Vaccine 9:190-193, 1991
25. Coulie PG, Somville M, Lehmann F, et al: Precursor frequency analysis of human cytotoxic T lymphocytes directed against autologous melanoma cells. Int J Cancer 50:289-297, 1992
26. Taswell C: Limiting dilution assays for determination of immunocompetent cell frequencies: I. Data analysis. J Immunol 126:1614-1619, 1981
27. McLaughlin JP, Schlom J, Kantor JA, et al: Improved immunotherapy of a recombinant CEA vaccinia vaccine when given in combination with interleukin-2. Cancer Res 56:2361-2367, 1996